VectorY
VectorY Therapeutics
Amsterdam, Netherlands · Founded 2020 · $175.6M raised
- Headquarters
- Amsterdam
- Employees
- 51–200
- Founded
- 2020
- Business Model
- B2B
- Website
- vectorytx.com
- Total Funding
- $175.6M
- Last Round
- $138.0M Series ANov 2023
- Rounds
- 2
About
VectorY Therapeutics is an Amsterdam-based fully integrated gene therapy company developing vectorized antibody treatments for neurodegenerative diseases including ALS. Founded in August 2020, VectorY combines AAV-based gene therapy with antibody science and operates proprietary R&D and GMP manufacturing facilities at Amsterdam Science Park.
Summary
VectorY is a Life Sciences company based in Amsterdam, Netherlands, founded in 2020. It has raised $175.6M in total across 2 rounds, most recently a $138.0M Series A round in Nov 2023. Investors include Forbion Growth Opportunities Fund, EQT AB and Forbion Capital Partners.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...
BridgeBio makes targeted treatments for genetic diseases.